FATE THERAPEUTICS INC
FATENASDAQTrading Snapshot
- Day Range
- $2.39 – $2.43
- 52-Week Range
- $0.95 – $3.23
- Volume
- $2.01B
- Avg Volume
- $2.10B
- Shares Outstanding
- 116.6M
- Next Earnings
- Dec 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $7M
- Last Q Revenue
- $2M
- P/E Ratio
- -2.3
- P/S Ratio
- 43.2x
- EPS (TTM)
- $-1.05
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.8%
Why Investors Own FATE
- ✓High-growth profile — revenue up +47.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 61% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
FATE THERAPEUTICS INC
FATE
StockOtter · stockotter.spaceAbout FATE THERAPEUTICS INC
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
CIRM backs Fate’s FT819 lupus trial
What happened Fate Therapeutics, Inc. (NASDAQ: FATE) said the California Institute for Regenerative Medicine awarded it a $15.0 million CLIN2 grant on September 25, 2026. The grant supports RECLAIM-LN, a Phase 2, potenti
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus Nephritis
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-der
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-der
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-der
BlackRock Inc. Makes New Investment in Fate Therapeutics, Inc. $FATE
BlackRock Inc. acquired a new position in shares of Fate Therapeutics, Inc. (NASDAQ: FATE) in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 7,298,895 sha